Aims We present the first analysis of the management and outcomes of stage III non-small
cell lung cancer (NSCLC) conducted in England using National Lung Cancer Audit data. …

Background Programmed death-ligand 1 (PD-L1) expression on cancer cells is a clinically
important biomarker to select patients with non-small cell lung cancer (NSCLC) for treatment …

Introduction Optimal management of people with advanced NSCLC depends on accurate
identification of predictive markers. Yet, real-world data in this setting are limited. We describe …

Introduction Data from the National Lung Cancer Audit (NLCA) often show variation in outcomes
between lung cancer units which are not entirely explained by case mix. We explore the …

Introduction The optimal management of lung cancer patients with metastatic involvement of
the ipsilateral mediastinum (N2 disease) remains controversial. Randomised controlled …

Background The National Lung Cancer Audit (NLCA) produces annual reports detailing
standards of care for lung cancer. This further analysis investigates the use of curative intent …

Introduction Long term prophylactic macrolide therapy is commonly used in respiratory diseases
characterised by persistent airway inflammation and chronic bacterial infection. There is …

Lung cancer outcomes in the UK show significant variation which are not entirely explained
by case mix. Differences in access to lung cancer services contribute. However, the specific …

Introduction National cancer audit data consistently report variation in care and outcomes
which is not entirely explained by case mix. The organisation and delivery of healthcare …

… was developed by JB, TS and NC. The study was conceived by JB and NC and designed by
JB, NC … The manuscript was drafted by NC and JB and reviewed by all authors prior to final …